NTLA · Intellia Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.05M | - | $13.78M | $14.24M | $16.63M | - | $9.11M | $6.96M | $28.93M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $80.74M | - | $94.75M | $97.03M | $108.43M | - | $123.38M | $114.21M | $111.85M | - |
| SG&A | $34.84M | - | $30.51M | $27.21M | $29.01M | - | $30.50M | $31.79M | $31.09M | - |
| Total Operating Expenses | $115.58M | - | $125.26M | $124.24M | $137.43M | - | $153.88M | $146.00M | $142.94M | - |
| D&A | $2.20M | - | $2.40M | $2.60M | $2.50M | - | - | - | $2.51M | - |
| Operating Income | ($100.53M) | - | ($111.48M) | ($110.00M) | ($120.81M) | - | ($144.77M) | ($139.04M) | ($114.00M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($96.23M) | - | ($101.32M) | ($101.25M) | ($114.33M) | - | ($135.71M) | ($146.97M) | ($107.44M) | - |
| EPS - Basic | ($0.81) | - | ($0.92) | ($0.98) | ($1.10) | - | ($1.34) | ($1.52) | ($1.12) | - |
| EPS - Diluted | ($0.81) | - | ($0.92) | ($0.98) | ($1.10) | - | ($1.34) | ($1.52) | ($1.12) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $134.70M | $155.46M | $193.39M | $156.17M | $126.88M | $189.18M | $120.50M | $130.85M | $171.98M | $226.75M |
| Accounts Receivable | $9.13M | $9.47M | $11.05M | $11.35M | $10.50M | $8.52M | $8.85M | $12.33M | $36.43M | $36.46M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $18.80M | $20.25M | $13.26M | $9.80M | $12.36M | $14.59M | $13.14M | $18.82M | $13.69M | $7.45M |
| Current Assets | $466.45M | $527.71M | $581.94M | $495.94M | $551.39M | $639.86M | $710.90M | $757.21M | $884.04M | $998.33M |
| Total Assets | $758.78M | $842.13M | $925.27M | $898.89M | $986.16M | $1.19B | $1.17B | $1.19B | $1.26B | $1.30B |
| Current Liabilities | $76.44M | $103.88M | $93.73M | $95.50M | $112.59M | $110.85M | $105.68M | $105.09M | $97.91M | $115.21M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $137.84M | $170.73M | $176.85M | $183.64M | $206.24M | $319.06M | $210.74M | $220.47M | $223.45M | $250.81M |
| Stockholders' Equity | $620.94M | $671.39M | $748.42M | $715.25M | $779.92M | $871.96M | $962.62M | $971.06M | $1.04B | $1.05B |
| Retained Earnings | ($2.69B) | ($2.59B) | ($2.49B) | ($2.39B) | ($2.29B) | ($2.18B) | ($2.05B) | ($1.91B) | ($1.77B) | ($1.66B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($117.35M) | - | - | - | ($148.93M) | - | - | - | ($120.66M) | - |
| Investing Cash Flow | $66.31M | - | - | - | $94.33M | - | - | - | $5.90M | - |
| Financing Cash Flow | $33.57M | - | - | - | $0 | - | - | - | $59.99M | - |
| CapEx | $79.0K | - | - | - | $735.0K | - | - | - | $2.51M | - |
| Free Cash Flow | ($117.42M) | - | - | - | ($149.66M) | - | - | - | ($123.17M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -668.1% | - | -808.9% | -772.2% | -726.6% | - | -1589.0% | -1998.6% | -394.0% | - |
| EBITDA margin | -653.4% | - | -791.4% | -753.9% | -711.5% | - | - | - | -385.3% | - |
| Net margin | -639.5% | - | -735.2% | -710.8% | -687.6% | - | -1489.5% | -2112.6% | -371.3% | - |
| Free cash flow margin | -780.3% | - | - | - | -900.1% | - | - | - | -425.7% | - |
| FCF / Net income | 1.22 | - | - | - | 1.31 | - | - | - | 1.15 | - |
| R&D / Revenue | 536.5% | - | 687.5% | 681.2% | 652.1% | - | 1354.2% | 1641.6% | 386.5% | - |
| SG&A / Revenue | 231.5% | - | 221.4% | 191.0% | 174.5% | - | 334.8% | 457.0% | 107.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.7% | - | -11.0% | -11.3% | -11.6% | - | -11.6% | -12.3% | -8.5% | - |
| Return on equity | -15.5% | - | -13.5% | -14.2% | -14.7% | - | -14.1% | -15.1% | -10.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.10 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 |
| Quick ratio | 6.10 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 |
| Cash ratio | 1.76 | 1.50 | 2.06 | 1.64 | 1.13 | 1.71 | 1.14 | 1.25 | 1.76 | 1.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.22 | 1.25 | 1.24 | 1.26 | 1.26 | 1.37 | 1.22 | 1.23 | 1.22 | 1.24 |
| Liabilities / Assets | 0.18 | 0.20 | 0.19 | 0.20 | 0.21 | 0.27 | 0.18 | 0.19 | 0.18 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.01 | 0.02 | 0.02 | - | 0.01 | 0.01 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 221d | - | 293d | 291d | 231d | - | 355d | 647d | 460d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.4x | - | 2.5x | 1.4x | 0.9x | - | 2.2x | 2.2x | 2.5x | - |
| P / S | 100.9x | - | 138.1x | 68.3x | 44.3x | - | 227.8x | 312.0x | 90.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.5% | - | 51.3% | 104.8% | -42.5% | - | -24.0% | -48.8% | 129.5% | - |
| Revenue CAGR (3y) | 6.1% | - | 1.3% | 0.5% | 13.9% | - | 8.1% | 2.0% | 65.0% | - |
| Revenue CAGR (5y) | 18.5% | - | -9.1% | -2.6% | 5.2% | - | -3.0% | -9.0% | 22.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 16.8% | - | 23.0% | 20.9% | -6.0% | - | -10.4% | -5.1% | -1.8% | - |
| Net income growth (YoY) | 15.8% | - | 25.3% | 31.1% | -6.4% | - | -11.0% | -18.8% | -4.2% | - |
| EPS growth (YoY) | 26.4% | - | 31.3% | 35.5% | 1.8% | - | 2.9% | -8.6% | 42.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 21.5% | - | - | - | -21.5% | - | - | - | -8.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -20.4% | -23.0% | -22.3% | -26.3% | -24.7% | -17.0% | -7.2% | -12.1% | -13.0% | -15.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$200.0K totalResearch Materials Shippmet Services$200.0K · 100.0%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Intellia Therapeutics against the 5 most active filers in the same SIC group.